EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Oncolytic HSV and cancer drug interactions: Current clinical status and future directions

Karina Vázquez-Arreguín, Kimberly A Rivera-Caraballo, Divya Ventarapragada, E Antonio Chiocca, Balveen Kaur

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.07.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025. Verfasst von Karina Vázquez-Arreguín und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms, Simplexvirus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic herpes simplex viruses (oHSVs) are engineered to target and replicate specifically in tumor cells, minimizing damage to normal tissues. This live virus biotherapy entails direct tumor cell killing followed by stimulation of antitumor immunity, leading to abscopal effects in untreated lesions. Currently, there are two clinically approved oHSV biotherapeutics: Imlygic, marketed by Amgen for the treatment of advanced melanoma in the United States and Europe, and Delytact, conditionally approved for recurrent brain tumors in Japan. Lessons learned from initial testing in patients have led to the development of second-generation viruses designed to improve tumor cytotoxicity and/or antitumor immune responses. Preclinical research has also uncovered numerous virus-drug interactions predicted to be synergistic. This has resulted in numerous clinical trials that are currently evaluating these second-generation viruses as single agents or in combination with other antineoplastic therapeutics. As of this review, there are more than 100 clinical trials evaluating their safety and efficacy. Here, we lay out a summary of oHSVs and the rationale behind various virus-drug combinations in clinical trials for patients with different malignancies. We provide a comprehensive review that details the underlying mechanisms of oHSV design and virus-drug interactions that form the basis of their clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsSimplexvirusAntineoplastic AgentsHumansAnimalsClinical Trials as TopicDrug Interactions

Stichwörter der Autor:innen

clinical trialscombination therapyimmunotherapyoncolytic herpesvirussolid tumorsvirotherapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
  • Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA; Cancer Biology Program, Graduate School of Biomedical Sciences, University of Texas MD Anderson…
  • Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
  • Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School, Brigham and Women's Hospital, Mass General Brigham, Boston, MA 02115, USA.
  • Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA. Electronic address: bkaur@augusta.edu.

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health

Zitieren

APA

Vázquez-Arreguín, K., Rivera-Caraballo, K. A., Ventarapragada, D., Chiocca, E. A., & Kaur, B. (2025). Oncolytic HSV and cancer drug interactions: Current clinical status and future directions. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.07.034

Vancouver

Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, Kaur B. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.07.034

BibTeX
@article{VzquezArregun2025,
  author = {Vázquez-Arreguín, Karina and Rivera-Caraballo, Kimberly A and Ventarapragada, Divya and Chiocca, E Antonio and Kaur, Balveen},
  title = {Oncolytic HSV and cancer drug interactions: Current clinical status and future directions},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.07.034}
}
Kostenlos starten →